恩杂鲁胺联合[177Lu]Lu-PSMA-617用于转移性去势抵抗性前列腺癌患者(ENZA-p):一项开放标签、多中心、随机、2期试验
ENZA-p研究在澳大利亚15家医院纳入162例转移性去势抵抗性前列腺癌患者,随机接受恩杂鲁胺联合自适应剂量[177Lu]Lu-PSMA-617或恩杂鲁胺单药一线治疗。联合组中位PSA无进展生存期为13.0个月,单药组为7.8个月(HR 0.43,95%CI 0.29-0.63,p<0.0001)。联合治疗改善了PSA无进展生存期,但需在更广泛转移性前列腺癌人群中进一步评估。
要点
- 联合组中位PSA无进展生存期13.0个月,单药组7.8个月,HR 0.43(95%CI 0.29-0.63,p<0.0001)。
- 联合组最常见不良事件为疲乏(75%)、恶心(47%)和口干(40%)。
- 两组3-5级不良事件发生率相似:联合组40%,单药组41%。
主要发现
- 联合组中位PSA无进展生存期为13.0个月(95%CI 11.0-17.0),单药组为7.8个月(95%CI 4.3-11.0),HR 0.43(95%CI 0.29-0.63,p<0.0001)。
- 联合组最常见不良事件(所有级别)为疲乏61例(75%)、恶心38例(47%)、口干32例(40%)。
- 单药组最常见不良事件(所有级别)为疲乏55例(70%)、恶心21例(27%)、便秘18例(23%)。
- 3-5级不良事件:联合组32例(40%),单药组32例(41%)。
- 仅见于联合组的3级事件包括贫血3例(4%)和血小板计数降低1例(1%);中心审查显示两组均无归因于治疗的4级或5级事件。
局限性
- 作者在结论中指出该联合方案需在更广泛的转移性前列腺癌中进一步评估。
- 本分析为中期分析,中位随访20个月(IQR 18-21),参与者随访仍在进行中。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Enzalutamide and lutetium-177 [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic castration-resistant prostate cancer. Androgen and PSMA receptors have a close intracellular relationship, with data suggesting complementary benefit if targeted concurrently. In this study, we assessed the activity and safety of enzalutamide plus adaptive-dosed [177Lu]Lu-PSMA-617 versus enzalutamide alone as first-line treatment for metastatic castration-resistant prostate cancer. METHODS: ENZA-p was an open-label, randomised, controlled phase 2 trial done at 15 hospitals in Australia. Participants were men aged 18 years or older with metastatic castration-resistant prostate cancer not previously treated with docetaxel or androgen receptor pathway inhibitors for metastatic castration-resistant prostate cancer, gallium-68 [68Ga]Ga-PSMA-PET-CT (PSMA-PET-CT) positive disease, Eastern Cooperative Oncology Group performance status of 0-2, and at least two risk factors for early progression on enzalutamide. Participants were randomly assigned (1:1) by a centralised, web-based system using minimisation with a random component to stratify for study site, disease burden, use of early docetaxel, and previous treatment with abiraterone acetate. Patients were either given oral enzalutamide 160 mg daily alone or with adaptive-dosed (two or four doses) intravenous 7·5 GBq [177Lu]Lu-PSMA-617 every 6-8 weeks dependent on an interim PSMA-PET-CT (week 12). The primary endpoint was prostate-specific antigen (PSA) progression-free survival, defined as the interval from the date of randomisation to the date of first evidence of PSA progression, commencement of non-protocol anticancer therapy, or death. The analysis was done in the intention-to-treat population, using stratified Cox proportional hazards regression. This trial is registered with ClinicalTrials.gov, NCT04419402, and participant follow-up is ongoing. FINDINGS: 162 participants were randomly assigned between Aug 17, 2020, and July 26, 2022. 83 men were assigned to the enzalutamide plus [177Lu]Lu-PSMA-617 group, and 79 were assigned to the enzalutamide group. Median follow-up in this interim analysis was 20 months (IQR 18-21), with 32 (39%) of 83 patients in the enzalutamide plus [177Lu]Lu-PSMA-617 group and 16 (20%) of 79 patients in the enzalutamide group remaining on treatment at the data cutoff date. Median age was 71 years (IQR 64-76). Median PSA progression-free survival was 13·0 months (95% CI 11·0-17·0) in the enzalutamide plus [177Lu]Lu-PSMA-617 group and 7·8 months (95% CI 4·3-11·0) in the enzalutamide group (hazard ratio 0·43, 95% CI 0·29-0·63, p<0·0001). The most common adverse events (all grades) were fatigue (61 [75%] of 81 patients), nausea (38 [47%]), and dry mouth (32 [40%]) in the enzalutamide plus [177Lu]Lu-PSMA-617 group and fatigue (55 [70%] of 79), nausea (21 [27%]), and constipation (18 [23%]) in the enzalutamide group. Grade 3-5 adverse events occurred in 32 (40%) of 81 patients in the enzalutamide plus [177Lu]Lu-PSMA-617 group and 32 (41%) of 79 patients in the enzalutamide group. Grade 3 events that occurred only in the enzalutamide plus [177Lu]Lu-PSMA-617 group included anaemia (three [4%] of 81 participants) and decreased platelet count (one [1%] participant). No grade 4 or 5 events were attributed to treatment on central review in either group. INTERPRETATION: The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved PSA progression-free survival providing evidence of enhanced anticancer activity in patients with metastatic castration-resistant prostate cancer with risk factors for early progression on enzalutamide and warrants further evaluation of the combination more broadly in metastatic prostate cancer. FUNDING: Prostate Cancer Research Alliance (Movember and Australian Federal Government), St Vincent's Clinic Foundation, GenesisCare, Roy Morgan Research, and Endocyte (a Novartis company).
引用
- Emmett L, Subramaniam S, Crumbaker M, et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024. PMID: 38621400. doi:10.1016/S1470-2045(24)00135-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。